51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
8 citations
,
December 2007 in “Journal of Thoracic Oncology” Erlotinib can cause significant but temporary hair loss in lung cancer patients.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia”
13 citations
,
January 2011 in “Lung India” Stopping isoniazid can reverse hair loss caused by the drug.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
March 2026 in “Indian Journal of Dermatology” Baricitinib can cause excessive hair growth.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.